CellaVision AB
C26
Company Profile
Business description
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers or software.
Contact
Mobilvagen 12
Lund22362
SWET: +46 464601600
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
248
Stocks News & Analysis
stocks
New production imminent for undervalued ASX gas play
LNG project receives first commissioning gas.
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
stocks
Why I dislike dividend stocks
If you need income then buying dividend stocks makes perfect sense. But if you don’t then it makes little sense because it’s likely to limit building real wealth. Here’s what you should do instead.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,293.20 | 45.10 | -0.48% |
CAC 40 | 8,174.20 | 14.39 | -0.18% |
DAX 40 | 23,830.99 | 441.20 | -1.82% |
Dow JONES (US) | 46,190.61 | 238.37 | 0.52% |
FTSE 100 | 9,354.57 | 81.52 | -0.86% |
HKSE | 25,247.10 | 641.41 | -2.48% |
NASDAQ | 22,679.97 | 117.44 | 0.52% |
Nikkei 225 | 47,582.15 | 695.59 | -1.44% |
NZX 50 Index | 13,289.21 | 99.89 | -0.75% |
S&P 500 | 6,664.01 | 34.94 | 0.53% |
S&P/ASX 200 | 8,995.30 | 34.70 | -0.38% |
SSE Composite Index | 3,839.76 | 76.47 | -1.95% |